Graft Versus Host Disease
Conditions
Interventions
exprerimental group:mostomatine 0.2g/m2×1d, busulfan 0.8mg/kg q6h×3d, cyclophosphamide 1.8g/m2×2d, cytarabine 2g/m2 q12h×2d, ATG 2.5mg/kg×3d, CD25 monoclonal antibody 1mg/kg×1d
Control group:mostomatine 0.2g/m2×1d, busulfan 0.8mg/kg q6h×3d, cyclophosphamide 1.8g/m2×2d, cytarabine 2g/m2 q12h×2d, ATG 2.5mg/kg×4d
Sponsors
Second Affiliated Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Allogeneic hematopoietic stem cell transplant recipients who receive haploid pretreatment protocol, and the pretreatment protocol is determined by the investigator; 2) Age= 18 years old, and = 60 years old; 3) KPS score > 60 points or ECOG score of 0~2 points; 4) The expected survival is greater than 3 months; 5) Those without serious damage to the function of important organs of the whole body; 6) Fully understand and inform the research and sign the informed consent form (ICF); Willing to follow and able to complete all trial procedures.
Exclusion criteria
Exclusion criteria: 1) Severe cardiac, renal or hepatic insufficiency; 2) Those who need treatment for other malignant tumors; 3) pregnant or lactating women; 4) Those who cannot follow up as scheduled; 5) Patients who cannot guarantee the completion of the necessary treatment plan and follow-up observation. 6) Researchers believe that other reasons are not suitable for clinical trial personnel.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute Graft Versus Host Disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hematopoietic reconstitution time after allogeneic hematopoietic stem cell transplantation;Level 3-4 aGVHD, cGVHD;infection rate;Total survival rate;Disease free survival rate;Transplant related mortality;Karnosky Quality of Life Assessment; | — |
Countries
China
Contacts
Public ContactZhu Lidan
Medical center of hemaotology, xinqiao hospital, Army medicl university
Outcome results
None listed